Surfing the MASH Tsunami

Send us Fan Mail I ncoming EASL Secretary General Prof. Thomas Berg, Global Liver Institute President and CEO Donna Cryer and Genfit Head of Global Diagnostics Suneil Hosmane share their unique perspectives on Digital ILC 2021 with Roger Green. In our lead-in episode for #ILC2021, Roger Green conducts interviews with three leaders, each with a unique perspective on what they value about this week&...

Send us Fan Mail Jörn Schattenberg, Naim Alkhouri, Dr. Michelle Long of Boston University and Livia Alimena of the Global Liver Institute join Roger to review highlights of Day Two at ILC2021. Each panelist reviewed a favorite presentation of the day, most of which involved learning about the nature of disease through large population analysis. In the course of the discussion, the group discussed...

Send us Fan Mail Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green identify specific sessions and presentations they believe will bring the greatest enlightenment around tough challenges and unaddressed issues in Fatty Liver disease. The topics the Surfers identify vary greatly, from cirrhosis to NITs to public policy issues such as the relationship between food insecurity and N...

Send us Fan Mail  Stephen Harrison and Jörn Schattenberg discuss what the titles of Digital ILC 2021 presentations tell us about possible findings in drug development. Drug development presentations will occur throughout Digital ILC 2021, ranging from late-breakers to general session presentations to dedicated sessions. Stephen and Jörn use the titles of presentation to discuss areas of drug devel...

Send us Fan Mail Jörn Schattenberg and the regular Surfers identify one thing about the Digital ILC 2021 meeting they anticipate eagerly and fall into a discussion about pharmacologic and non-pharmacologic approaches to managing metabolic issues. As the group looked forward to Digital ILC 2021, each panelist identified one source of particular excitement. The answers varied all the way from proces...

Send us Fan Mail  Joern Schattenberg joins the Surfers to identify exciting presentations and sessions from the Digital ILC 2021 meeting.  Digital ILC 2021 kicks off one week from today, with four days of sessions covering the entire range of liver topics. Professor Schattenberg joins Dr. Stephen Harrison, Louise Campbell and Roger Green in identifying presentations, sessions and major themes they...

Send us Fan Mail Global Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia VA Health Care System Chief of Hepatology and Gastroenterology Dr. Michael Fuchs discuss GLI's US NASH Action Plan and steps different stakeholders can take to support the Plan. In this conversation, the group considers systems issues ran...

Send us Fan Mail Global Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia VA Health Care System Chief of Hepatology and Gastroenterology Dr. Michael Fuchs discuss GLI's US NASH Action Plan and steps different stakeholders can take to support the Plan. In this conversation, the group discusses the need for commo...

Send us Fan Mail Global Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia VA Health Care System Chief of Hepatology and Gastroenterology Dr. Michael Fuchs discuss GLI's US NASH Action Plan and steps different stakeholders can take to support the Plan. In this conversation, Andrew discusses the genesis of the US...

Send us Fan Mail Global Liver Institute Director of Global Policy Andrew Scott walks a diverse set of stakeholders through the US NASH Action Plan, with special focus on education, awareness and clarity in diagnosis and treatment. In addition to Andrew, Becky Taub, Madrigal Pharmaceuticals co-founder, Director, CMO and President of Research & Development and Dr. Michael Fuchs, Acting Chief of...

Send us Fan Mail EASL Scientific Committee member Luca Valenti joins the Surfers to "crystal ball" potential key outcomes from Digital ILC 2021. The four panelists each predict one likely outcome from Digital ILC 2021. Interestingly, none of them focus specifically on clinical trials, but instead on a broader range of issues around understanding the metabolic underpinnings of NASH and de...

Send us Fan Mail EASL Scientific Committee member Luca Valenti joins the Surfers to discuss some of the issues that will be discussed at Digital ILC 2021. After Luca and Stephen Harrison discuss what they consider highlights of this month's Digital ILC meeting, Louise Campbell and Roger Green join them to discuss some of the key issues they anticipate being address at EASL's signature an...

Send us Fan Mail Stephen Harrison and EASL Scientific Committee member Luca Valenti Preview Highlights of the Digital ILC 2021. Luca and Stephen discuss what each of them consider highlights of this month's Digital ILC meeting, focusing not only on presentation and poster topics but also a new meeting platform with improved connectivity. This brief discussion will help you get in the right fr...

Send us Fan Mail EASL Scientific Organizing Committee member Prof. Luca Valenti joins the Surfers to discuss some of the major NAFLD-related topics we will learn more about at Digital ILC 2021. This episode begins with the announcement that Surfing the NASH Tsunami is an official Media Partner for Digital ILC 2021! The rest of the episode is devoted to discussing how the meeting came together, som...

Send us Fan Mail Global Liver Institute President and CEO Donna Cryer joins the Surfers to discuss International NASH Day 2021. This conversation takes a deeper look at NASH Day and also Global Liver Institute's growth and future plans. The 4th annual International NASH Day is a major global institution, with endorsements from WHO, EASL, AASLD, at least 14 medical societies, and organizations...

Send us Fan Mail Global Liver Institute President and CEO Donna Cryer joins the Surfers to discuss International NASH Day 2021. This conversation provides and overview of the day's event. The 4th annual International NASH Day is a major global institution, with endorsements from WHO, EASL, AASLD, at least 14 medical societies, and organizations in at least 26 countries, and more than 100,000...

Send us Fan Mail Roger Green narrates a series of interviews, conversations and viewpoints about NGM Biopharmaceuticals discontinuing its F2/F3 aldafermin program The SurfingNASH team weaves interviews, conversations and text notes from 9 stakeholders, including US and EU KOLs, program heads, treating physicians, patient advocates and NASH patients into a narrative addressing key issues. Was the A...

Send us Fan Mail Global Liver Institute President and CEO Donna Cryer joins the Surfers to discuss International NASH Day 2021. Last year's IND had 100+ participants. This year will be bigger! Learn why. The 4th annual International NASH Day is a major global institution, with endorsements from WHO, EASL, AASLD, at least 14 medical societies, and organizations in at least 26 countries. Global...

Send us Fan Mail azen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therapy after current Phase 2b and Phase 3 candidates have been approved. This conversation considers how the idea that front-line treaters will be PCPs might affect treatment patterns. This conversation starts with Roger Green pointing out that most real-world patient treatment decision...

Send us Fan Mail Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 candidates have been approved. This conversation examines the prospect for different kinds of backbone strategies.  At one extreme, many chronic therapies have a single monotherapy backbone agent, like what metformin has been to Type 2 diabetes....

Send us Fan Mail Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 candidates have been approved. This conversation lays out basic premises.  In this conversation, Stephen Harrison and Mazen focus on how treatment guidelines and therapeutic choices might vary for patients starting at F2 vs. F3 vs. compensated (...

Send us Fan Mail Mazen Noureddin joins the Surfers to explore the issues and needs that will shape treatment guidelines in a world after NASH drugs come to market. In Season 2 Episode 16, a discussion of cost-effectiveness led to the question, "How will treatment pathways and rules evolve as new NASH drugs come to market." Mazen Noureddin, who raised this issue with Stephen Harrison in t...

Send us Fan Mail ( This episode has been reposted to include the complete conversation content.) Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gowrieh share key findings from their 20210 Journal of Hepatology paper titled "Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort." The 2021 Journa...

Send us Fan Mail ( This episode has been reposted to include the complete conversation content.) Louise Campbell and Roger Green join co-authors Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gowrieh to dive deeper into key findings from the 2021 Journal of Hepatology paper titled "Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepati...

Send us Fan Mail ( This episode has been reposted to include the complete conversation content.) Louise Campbell and Roger Green join co-authors Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gowrieh to discuss why this epidemiology paper from the 2021 Journal of Hepatology is an urgent call to action on NAFLD and NASH screening and treatment.  Considered in its totality, the dat...